- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04512846
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
June 24, 2023 updated by: Beijing 302 Hospital
Comparison of Efficacy in Stereotactic Body Radiation Therapy (SBRT) of Large Hepatocellular Carcinoma (5-10 cm) With or Without Transcatheter Arterial Chemoembolization (TACE)
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xuezhang Duan
- Phone Number: +8613621386161
- Email: duanxuezhang2006@163.com
Study Contact Backup
- Name: Jing Sun
- Phone Number: +8613718681094
- Email: 519299998@qq.com
Study Locations
-
-
-
Beijing, China, 100039
- Recruiting
- Beijing 302 Hospital
-
Contact:
- Jing Sun
- Phone Number: +8613718681094
- Email: 519299998@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The large HCC patients who receive SBRT with or without TACE.
Description
Inclusion Criteria:
- primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
- single lesion and longest tumor diameter were 5-10cm;
- CP-A or B classification;
- Eastern Cooperative Oncology Group (ECOG) score 0-1;
- distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm
- unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc.
- rejecting other therapies such as resection, liver transplantation, etc.
- platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
- patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.
Exclusion Criteria:
- tumor thrombus;
- lymph node involvement;
- extrahepatic metastasis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
CK-SBRT with TACE group
The hepatocellular carcinoma patients (5-10cm)who received SBRT with TACE.
|
CK-SBRT group
The hepatocellular carcinoma patients (5-10cm)who received SBRT alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival time
Time Frame: From date of randomization until the date of death from any cause, assessed up to 36 months
|
OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.
|
From date of randomization until the date of death from any cause, assessed up to 36 months
|
Progression-free survival time
Time Frame: From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months
|
PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.
|
From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months
|
Local control time
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radiation-induced liver injury rates
Time Frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
|
From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
|
Adverse reaction
Time Frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
|
From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer. 2016 Nov 3;16(1):834. doi: 10.1186/s12885-016-2894-9.
- Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019 Mar;28:228-235. doi: 10.1016/j.suronc.2019.01.006. Epub 2019 Jan 29.
- Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. doi: 10.1118/1.3438081. Erratum In: Med Phys. 2012 Jan;39(1):563. Dosage error in article text. Med Phys. 2023 Jan 25;:
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Estimated)
August 1, 2023
Study Completion (Estimated)
August 30, 2026
Study Registration Dates
First Submitted
August 11, 2020
First Submitted That Met QC Criteria
August 11, 2020
First Posted (Actual)
August 14, 2020
Study Record Updates
Last Update Posted (Actual)
June 27, 2023
Last Update Submitted That Met QC Criteria
June 24, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- large HCC with/without TACE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stereotactic Body Radiation Therapy
-
Peking University Third HospitalNot yet recruitingStereotactic Body Radiation TherapyChina
-
Instituto de Investigación en Oncología Radioterápica...Instituto de Investigación en Oncología Radioterápica FEOR (IRAD-FEOR)RecruitingProstate Cancer | Stereotactic Body Radiation TherapySpain
-
Peking University Third HospitalRecruitingRecurrent Cancer | Stereotactic Body Radiation Therapy | Thoracic Tumor | Irradiation; ReactionChina
-
First People's Hospital of HangzhouHangzhou Cancer HospitalRecruitingStereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLCChina
-
Galera Therapeutics, Inc.M.D. Anderson Cancer CenterCompletedPancreatic Cancer | Stereotactic Body Radiation TherapyUnited States
-
University of Wisconsin, MadisonSuspendedLiver Metastases | Stereotactic Body Radiation Therapy | MRI-guided TreatmentUnited States
-
Hangzhou Cancer HospitalUnknownEsophageal Cancer | Stereotactic Body Radiation Therapy | Metastatic Esophageal Cancer | ThymalfasinChina
-
Beijing 302 HospitalRecruitingStereotactic Body Radiation Therapy | Transcatheter Arterial Chemoembolization | Small Hepatocellular CarcinomaChina
-
Peking University Third HospitalHuashan Hospital; Tianjin Medical UniversityUnknownStereotactic Body Radiation TherapyChina
-
Peking University Third HospitalHuashan Hospital; Tianjin Medical UniversityCompletedStereotactic Body Radiation TherapyChina